CSL Biotherapies, a subsidiary of CSL Ltd., has been awarded a contract by the U.S. Department of Health and Human Services to supply pre-pandemic and pandemic vaccine antigens and related services for the U.S. stockpile. The contract has a maximum potential value of $1.5 billion if all options are exercised under the contract.
CSL Biotherapies may manufacture and store bulk antigen for influenza strains with pandemic potential, as well as develop working virus 'seeds' for other manufacturers and to formulate, fill and finish bulk stored antigen.
"We are very pleased to again be working with the U.S. government on its pandemic preparedness efforts," said Dr. John Anderson, senior vice president of CSL Biotherapies. "CSL Biotherapies is committed to helping to protect the American public against the potential impact of an influenza pandemic. We are proud to contribute our 45 years of successful influenza vaccine manufacturing experience to the U.S. National Strategy for Pandemic Influenza."